{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:00:21Z","timestamp":1777914021656,"version":"3.51.4"},"reference-count":97,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:p>Gene-engineered T-cell therapies have the potential to revolutionize the treatment of cancer. These therapies have shown exceptional clinical efficacy specifically in the field of B-cell malignancies and the first products (Kymriah\u2122 and Yescarta\u2122) have recently been approved in the United States for specific indications. The power of these treatments is also linked with a distinct set of toxicities both predicted and unpredicted, including off-tumor activity, cytokine release syndromes, and neurotoxicity, occasionally with fatal consequences. As these therapies begin to reach more patients, it is critical to develop the nonclinical tools to adequately determine the mechanisms driving these toxicities, to assess the safety risks of candidate products, and to develop strategies for safety management.<\/jats:p>","DOI":"10.1177\/0192623317752101","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T23:20:50Z","timestamp":1519341650000},"page":"131-146","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-4639","authenticated-orcid":false,"given":"Michaela E.","family":"Sharpe","sequence":"first","affiliation":[{"name":"Cell and Gene Therapy Catapult, Guy\u2019s Hospital, Great Maze Pond, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"bibr1-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2013.022"},{"key":"bibr2-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12622"},{"key":"bibr3-0192623317752101","doi-asserted-by":"publisher","DOI":"10.4103\/0975-1483.66810"},{"key":"bibr4-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.075"},{"key":"bibr5-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0170"},{"key":"bibr6-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.11.011"},{"key":"bibr7-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0163"},{"key":"bibr8-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3246"},{"key":"bibr9-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.31"},{"key":"bibr10-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"bibr11-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"bibr110-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006034"},{"key":"bibr12-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1641-9"},{"key":"bibr13-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.09.008"},{"key":"bibr14-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061338"},{"key":"bibr15-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"bibr16-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.6441"},{"key":"bibr17-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"bibr18-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.97"},{"key":"bibr19-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504542"},{"key":"bibr20-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050732"},{"key":"bibr21-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-P14"},{"key":"bibr22-0192623317752101","unstructured":"Gerry A. B. (2016). Preclinical safety testing of enhanced-affinity TCRs. European Medicines Agency. Accessed October 14, 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Presentation\/2016\/12\/WC500217500.pdf."},{"key":"bibr23-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-0490"},{"key":"bibr24-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"bibr25-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"bibr26-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35700"},{"key":"bibr27-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088547"},{"key":"bibr28-0192623317752101","unstructured":"Harris J. (2017). Kite reports cerebral edema death in ZUMA-1 CAR T-cell trial. Onc Live. Accessed December 23, 2017. http:\/\/www.onclive.com\/web-exclusives\/kite-reports-cerebral-edema-death-in-zuma1-car-tcell-trial."},{"key":"bibr29-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"bibr30-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.75"},{"key":"bibr31-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211714"},{"key":"bibr32-0192623317752101","doi-asserted-by":"crossref","unstructured":"Kaiser J. (2017). Modified T cells that attack leukemia become first gene therapy approved in the United States. Science. Accessed October 31, 2017. http:\/\/www.sciencemag.org\/news\/2017\/08\/modified-t-cells-attack-leukemia-become-first-gene-therapy-approved-united-states.","DOI":"10.1126\/science.aap8293"},{"key":"bibr33-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"key":"bibr34-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"bibr35-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"bibr36-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-265041"},{"key":"bibr37-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0160"},{"key":"bibr38-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0354"},{"key":"bibr39-0192623317752101","doi-asserted-by":"publisher","DOI":"10.4161\/onci.18851"},{"key":"bibr40-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.17"},{"key":"bibr41-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.9964"},{"key":"bibr42-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"bibr43-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"bibr44-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2016.12.006"},{"key":"bibr45-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490565"},{"key":"bibr46-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.3040"},{"key":"bibr47-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3000"},{"issue":"278093","key":"bibr48-0192623317752101","volume":"2012","author":"Maher J.","year":"2012","journal-title":"ISRN Oncol"},{"key":"bibr49-0192623317752101","first-page":"381","volume":"84","author":"Mansh M.","year":"2011","journal-title":"Yale J Biol Med"},{"key":"bibr50-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"key":"bibr51-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"bibr52-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"bibr53-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527622"},{"key":"bibr54-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182829903"},{"key":"bibr55-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"bibr56-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700100"},{"key":"bibr57-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0666"},{"key":"bibr58-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"bibr59-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.4.1063"},{"key":"bibr60-0192623317752101","unstructured":"Novartis. (2017). CTL019 (tisagenlecleucel): In pediatric and young adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia. Accessed October 31, 2017. https:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/oncologicdrugsadvisorycommittee\/ucm567385.pdf."},{"key":"bibr61-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32835822f5"},{"key":"bibr62-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7024"},{"key":"bibr63-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.272"},{"key":"bibr64-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.305"},{"key":"bibr65-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1711.2005.01371.x"},{"key":"bibr66-0192623317752101","unstructured":"Plieth J. (2017). Spotlight\u2014Putting a number on CAR-T deaths. EPVantage. Accessed October 31, 2017. http:\/\/epvantage.com\/Universal\/View.aspx?type=Story&id=716231&isEPVantage=yes."},{"key":"bibr67-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1982.1982"},{"key":"bibr68-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"bibr69-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"bibr70-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"bibr71-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000"},{"key":"bibr72-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3910"},{"key":"bibr73-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0410-x"},{"key":"bibr74-0192623317752101","unstructured":"Reuters. (2017). Juno ends development of high-profile leukemia drug after deaths. Accessed December 23, 2017. https:\/\/www.reuters.com\/article\/us-juno-leukemia\/juno-ends-development-of-high-profile-leukemia-drug-after-deaths-idUSKBN1685QQ."},{"key":"bibr75-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3161"},{"key":"bibr76-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0493"},{"key":"bibr77-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011"},{"key":"bibr78-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12136"},{"key":"bibr79-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1038\/nrc971"},{"key":"bibr80-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3019"},{"key":"bibr81-0192623317752101","first-page":"101","volume":"4","author":"Sarno J.","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"bibr82-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003761"},{"key":"bibr83-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.018036"},{"key":"bibr84-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.651.651"},{"key":"bibr85-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"bibr86-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1177\/0192623310362249"},{"key":"bibr87-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"bibr88-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"bibr89-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519"},{"key":"bibr90-0192623317752101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301523"},{"key":"bibr91-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12143"},{"key":"bibr92-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.012"},{"key":"bibr93-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9689-9"},{"key":"bibr94-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006957"},{"key":"bibr95-0192623317752101","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.242600099"},{"key":"bibr96-0192623317752101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103495"}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623317752101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0192623317752101","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623317752101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:39:10Z","timestamp":1777653550000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0192623317752101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1177\/0192623317752101"],"URL":"https:\/\/doi.org\/10.1177\/0192623317752101","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}